Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial.
Lancet Rheumatol
; 2(12): e743-e753, 2020 Dec.
Article
in En
| MEDLINE
| ID: mdl-34966900
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
/
Prognostic_studies
Language:
En
Journal:
Lancet Rheumatol
Year:
2020
Document type:
Article
Country of publication: